Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans

Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers 3 main topics including systemic therapies, treatment of the primary and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy and ultimately cure, especially when treating the primary. Dr. Morgans address the question of what should now be considered the standard of care for the treatment of metastatic hormone-sensitive prostate cancer. ADT alone is not sufficient for the majority of patients with metastatic hormone-sensitive disease and treatment should consist of ADT plus either docetaxel or abiraterone, depending on chemo eligibility, patient preference and other factors including the burden of disease, performance status and overall health of the patient. Looking to the future Dr. Morgans addresses the potential need for multiple systemic therapies and triple drug combinations to achieve the goals of therapy in a larger number of patients.


Alicia Morgans, MD, MPH, is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Charles J. Ryan, MD, The B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.